Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS
Key oral presentations highlight new safety, efficacy and workflow improvements data to optimize irrigation and support consistent procedural outcomes.
YOKOHAMA, Japan, Nov. 3, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment1, today announced that new clinical and real-world data from its integrated-by-design VARIPULSE™ Platform in pulsed field ablation (PFA) procedures for atrial fibrillation (AF) will be presented at the Asia Pacific Heart Rhythm Society (APHRS) and the Japanese Heart Rhythm Society (JHRS) joint annual meeting, 12–15 November 2025 in Yokohama, Japan.
The fully integrated platform includes the VARIPULSE™ Catheter, TRUPULSE™ Generator, and CARTO™ 3 Mapping System VARIPULSE™ Software. The Platform is now approved for use in the United States, Europe, Asia Pacific, Canada, and Latin America. More than 25,000 procedures have been performed across the U.S., Europe, Canada, Japan, Hong Kong, Mainland China, Korea, Taiwan, and Australia.
Johnson & Johnson MedTech reaffirms its dedication to advancing scientific knowledge and fostering collaborations aimed at improving patient outcomes by presenting new clinical and real-world evidence from the VARIPULSE™ Platform. The company will also host a comprehensive series of science-based symposia, hands-on demonstrations, and educational sessions at APHRS and JHRS.
"The clinical evidence we're presenting at this year's APHRS and JHRS—highlighting our fully integrated-by-design CARTO™ 3 Mapping System and VARIPULSE™ Platform for pulsed field ablation—alongside a robust scientific program, immersive tech-suite experience, and forward-looking pipeline discussions, reflects our deep commitment and the comprehensive strength of our leading portfolio for atrial fibrillation and complex arrhythmias," said Jing Li, Vice President, Electrophysiology & Neurovascular, Asia Pacific MedTech, Johnson & Johnson.
Key data and presentations include:
- QUEST AF: Oral presentation on the "Acute success of persistent atrial fibrillation ablation with a temperature-controlled very high-power short-duration radiofrequency catheter: initial real-world experience from QUEST AF."
- VARIPURE (SECURE): Poster presentation on the "Real-world workflow, efficiency and vein-level analysis for a novel pulsed field ablation variable loop circular catheter in AF procedures: insights from VARIPURE."
- admIRE: Oral session on the "Impact of age and diagnosis-to-ablation time on sex differences in 12-month outcomes after catheter ablation for atrial fibrillation in addition to and oral presentation and hot line session on the "Procedural characteristics and clinical outcomes from same-day discharge after pulsed field ablation treatment for atrial fibrillation: an admIRE trial subanalysis."
- REAL AF:
- Poster viewing session on "Right-Sided First Pass Isolation: A Critical Marker of Ablation Efficacy in Atrial Fibrillation"
- Oral session on "Bilateral First Pass Isolation is a Key Procedural endpoint for Successful Atrial Fibrillation"
- Poster viewing session on "An Analysis of the Benefits of Carina Ablation as an Adjunct to Pulmonary Vein Isolation"
- Oral session on "A retrospective study of sex differences in left atrial scar burden and atrial fibrillation"
- Poster viewing session on "Sex Differences in Catheter Ablation Outcomes for Atrial Fibrillation"
Johnson & Johnson MedTech will continue collaborating with the clinical community to expand real-world evidence around the VARIPULSE™ Platform and accelerate patient-centered innovation in atrial fibrillation care.
| ___________________________ |
| 1 BWI Marketing Share Data 2019 |
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration, and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit biosensewebster.com.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in surgery, orthopaedics, vision, and cardiovascular solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to the VARIPULSETM Platform. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, warnings and precautions.
Caution: US law restricts this device to sale by or on the order of a physician.
© Johnson & Johnson and its affiliates 2025. M_US_ELP_THER_407762
Media contacts:
Carlos Taveras
[email protected]
Erin Farley
[email protected]
SOURCE Johnson & Johnson MedTech
Share this article